With so many manufacturers that have released vaccines for COVID, you sure have a lot of options in case you’re willing to get vaccinated for the coronavirus. However, a new study suggests that you should be more reluctant into getting injected with the vaccine developed by the Chinese brand Sinopharm compared to other jabs.
The Jerusalem Post brings the news about the new study in question. After over one million people’s data was analyzed, researchers found that the vaccine developed by Sinopharm is less suitable for those people above the age of 50 years old.
COVID vaccines made by Pfizer, AstraZeneca, and Sputnik V are several times better than the ones made by Sinopharm
The Bahraini study reveals that Sinopharm’s jab is significantly less efficient at confronting the virus than the vaccines developed by Pfizer, AstraZeneca, and Sputnik V.
Sinopharm’s vaccine was also found to reduce the death rate to a quarter compared to those people who didn’t get any vaccine shot.
Dr. Manaf AlQahtani, who is one of the authors of the new study and also a member of the Bahraini national medical team that tackles the coronavirus, declared for reporters as quoted by jpost.com:
We believed from the beginning that the vaccine helps curb the spread of the virus, but the main goal of it is to reduce complications in the event of infection and to reduce deaths or hospitalizations,
This study contributes to shaping future policies in adopting vaccines globally, and Bahrain has made a large imprint in the scientific community to provide this type of data.
Officials around the world remain pretty vocal in trying to convince the public to accept one of the COVID vaccines.
However, only 41.7% of the planet’s population has been vaccinated for the coronavirus with at least one of the necessary doses, according to Our World in Data.